An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2017
At a glance
- Drugs Buparlisib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Novartis
- 06 May 2017 This trial has been completed in Spain.
- 06 Mar 2017 Planned end date has changed from 1 Dec 2016 to 30 Jun 2017.
- 06 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 30 Jun 2017.